Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

EDT Aligos Therapeutics (ALGS) files to sell 6.25M shares of common stock for holdersLight Up your Portfolio with Spark:Easily identify ...

Two oral presentations will highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B virus (HBV) infection in both HBeAg-positive and HBeAg-negative subjects, ...

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 8.8% of Aligos Therapeutics ...

Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Aligos Therapeutics in a report issued on Tuesday, March 11th. HC Wainwright analyst E.

SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical ...

SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient ...

(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS,“Aligos”,“Company ...

SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...